CA2449698A1 - Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties - Google Patents
Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties Download PDFInfo
- Publication number
- CA2449698A1 CA2449698A1 CA002449698A CA2449698A CA2449698A1 CA 2449698 A1 CA2449698 A1 CA 2449698A1 CA 002449698 A CA002449698 A CA 002449698A CA 2449698 A CA2449698 A CA 2449698A CA 2449698 A1 CA2449698 A1 CA 2449698A1
- Authority
- CA
- Canada
- Prior art keywords
- formula
- compounds
- substantially monodispersed
- monodispersed mixture
- polymers
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
- C08G65/334—Polymers modified by chemical after-treatment with organic compounds containing sulfur
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L71/00—Compositions of polyethers obtained by reactions forming an ether link in the main chain; Compositions of derivatives of such polymers
- C08L71/02—Polyalkylene oxides
Abstract
Methods of synthesizing a substantially monodispersed mixture of polymers comprising polyethylene glycol moieties include: reacting a substantially monodispersed mixture of compounds having the structure of Formula I: R1(OC2H4)n-O-X+ (I) wherein R1 is H or a lipophilic moiety; n is from 1 to 2 5; and X+ is a positive ion, with a substantially monodispersed mixture of compounds having the structure of Formula II: R2(OC2H4)m-OMs (II) wherein R2 is H or a lipophilic moiety; and m is from 1 to 25,under conditions sufficie nt to provide a substantially monodispersed mixture of polymers comprising polyethylene glycol moieties and having the structure of Formula III: R2(OC2H4)m+n-OR1(III).
Claims (41)
1. A method of synthesizing a substantially monodispersed mixture of polymers comprising polyethylene glycol moieties, said method comprising:
reacting a substantially monodispersed mixture of compounds having the structure of Formula I:
R1(OC2H4)m-O-X+ (I) wherein R1 is H or a lipophilic moiety; m is from 1 to 25; and X+ is a positive ion, with a substantially monodispersed mixture of compounds having the structure of Formula II:
R2(OC2H4)n-OMs (II) wherein R2 is H or a lipophilic moiety; and n is from 1 to 25, under conditions sufficient to provide a substantially monodispersed mixture of polymers comprising polyethylene glycol moieties and having the structure of Formula III:
R2(OC2H4)m+n-OR1 (III).
reacting a substantially monodispersed mixture of compounds having the structure of Formula I:
R1(OC2H4)m-O-X+ (I) wherein R1 is H or a lipophilic moiety; m is from 1 to 25; and X+ is a positive ion, with a substantially monodispersed mixture of compounds having the structure of Formula II:
R2(OC2H4)n-OMs (II) wherein R2 is H or a lipophilic moiety; and n is from 1 to 25, under conditions sufficient to provide a substantially monodispersed mixture of polymers comprising polyethylene glycol moieties and having the structure of Formula III:
R2(OC2H4)m+n-OR1 (III).
2. The method according to Claim 1, wherein the molar ratio of the compounds of Formula I to the compounds of Formula II is greater than about 1:1.
3. The method according to Claim 1, wherein the molar ratio of the compounds of Formula I to the compounds of Formula II is at least about 2:1.
4. The method according to Claim 1, wherein R2 is a lipophilic moiety selected such that the polymers of Formula III are substantially insoluble in water.
5. The method according to Claim 1, wherein R2 is a lipophilic moiety selected such that the polymers of Formula III have a Log K ow greater than about 0.
6. The method according to Claim 1, wherein R2 is a fatty acid moiety or an ester of a fatty acid moiety.
7. The method according to Claim 6, wherein the fatty acid moiety or the ester of a fatty acid moiety comprises an alkyl moiety at least n carbon atoms in length.
8. The method according to Claim 7, wherein the molar ratio of the compounds of Formula I to the compounds of Formula II are greater than 1:1 such that the reaction of the compounds of Formula I with the compounds of Formula II provide a mixture comprising the polymers of Formula III and an excess of compounds of Formula I, said method further comprising:
separating the 1excess compounds of Formula I from the polymers of Formula III.
separating the 1excess compounds of Formula I from the polymers of Formula III.
9. The method according to Claim 8, wherein the separating step comprises:
contacting the mixture of the excess compounds of Formula I and the polymers of Formula III with an aqueous medium; and collecting the polymers of Formula III.
contacting the mixture of the excess compounds of Formula I and the polymers of Formula III with an aqueous medium; and collecting the polymers of Formula III.
10. The method according to Claim 8, wherein the separating step comprises:
contacting the mixture of the excess compounds of Formula I and the polymers of Formula III with an organic medium;
removing the excess of compounds of Formula I from the organic medium; and recovering the polymers of Formula III from the organic medium.
contacting the mixture of the excess compounds of Formula I and the polymers of Formula III with an organic medium;
removing the excess of compounds of Formula I from the organic medium; and recovering the polymers of Formula III from the organic medium.
11. The method according to Claim 1, further comprising:
reacting a substantially monodispersed mixture of compounds having the structure of Formula V:
R2(OC2H4)n-OH (V) with a methanesulfonyl halide under conditions sufficient to provide a substantially monodispersed mixture of compounds having the structure of Formula II:
R2(OC2H4)n-OM s (II).
reacting a substantially monodispersed mixture of compounds having the structure of Formula V:
R2(OC2H4)n-OH (V) with a methanesulfonyl halide under conditions sufficient to provide a substantially monodispersed mixture of compounds having the structure of Formula II:
R2(OC2H4)n-OM s (II).
12. The method according to Claim 11, wherein the methanesulfonyl halide is methane sulfonyl chloride.
13. The method according to Claim 11, wherein the molar ratio of the methanesulfonyl halide to the compounds of Formula V is greater than about 1:1.
14. The method according to Claim 11, wherein the molar ratio of the methanesulfonyl halide to the compounds of Formula V is at least about 2:1.
15. The method according to Claim 11, wherein the reacting of a substantially monodispersed mixture of compounds having a structure of Formula V with a methanesulfonyl halide to provide a substantially monodispersed mixture of compounds of Formula II is performed at a temperature between about 0°C and about 40°C.
16. The method according to Claim 11, wherein the reacting of a substantially monodispersed mixture of compounds of Formula V with a methanesulfonyl halide to provide a substantially monodispersed mixture of compounds of Formula II is performed at a temperature between about 15°C and about 35°C.
17. The method according to Claim 11, wherein the reacting of a substantially monodispersed mixture of compounds of Formula V with methane sulfonyl halide to provide a substantially monodispersed mixture compounds of Formula II is performed for a period of time between about 0.25 hours and about 2 hours.
18. The method according to Claim 11, further comprising:
reacting a substantially monodispersed mixture of compounds having the structure of Formula VI:
R2-OMs (VI) wherein R1 is a lipophilic moiety;
with a substantially monodispersed mixture of compounds having the structure of Formula VII:
R3(OC2H4)m-O-X2+ (VII) wherein R3 is benzyl, trityl, or trimethylsilyl; and X2+ is a positive ion;
under conditions sufficient to provide a substantially monodispersed mixture of compounds having the structure of Formula VIII:
R3(OC2H4)m-OR2 (VIII); and reacting the substantially monodispersed mixture of compounds having the structure of Formula VIII under conditions sufficient to provide a substantially monodispersed mixture of compounds having the structure of Formula V:
R2(OC2H4)m-OH (V).
reacting a substantially monodispersed mixture of compounds having the structure of Formula VI:
R2-OMs (VI) wherein R1 is a lipophilic moiety;
with a substantially monodispersed mixture of compounds having the structure of Formula VII:
R3(OC2H4)m-O-X2+ (VII) wherein R3 is benzyl, trityl, or trimethylsilyl; and X2+ is a positive ion;
under conditions sufficient to provide a substantially monodispersed mixture of compounds having the structure of Formula VIII:
R3(OC2H4)m-OR2 (VIII); and reacting the substantially monodispersed mixture of compounds having the structure of Formula VIII under conditions sufficient to provide a substantially monodispersed mixture of compounds having the structure of Formula V:
R2(OC2H4)m-OH (V).
19. The method according to Claim 18, wherein R3 is benzyl.
20. The method according to Claim 1, further comprising:
reacting a substantially monodispersed mixture of compounds having the structure of Formula IV:
R1(OC2H4)n-OH (IV) under conditions sufficient to provide a substantially monodispersed mixture of compounds having the structure of Formula I:
R1(OC2H4)n-O-X+ (I).
reacting a substantially monodispersed mixture of compounds having the structure of Formula IV:
R1(OC2H4)n-OH (IV) under conditions sufficient to provide a substantially monodispersed mixture of compounds having the structure of Formula I:
R1(OC2H4)n-O-X+ (I).
21. The method according to Claim 20, wherein the reacting of a substantially monodispersed mixture of compounds having a structure of Formula IV under conditions sufficient to provide a substantially monodispersed mixture of compounds of Formula I
comprises:
reacting a substantially monodispersed mixture of compounds having the structure of Formula IV with a compound capable of ionizing the hydroxyl moiety of the compound of Formula IV under conditions sufficient to provide the substantially monodispersed mixture of compounds having the structure of Formula I.
comprises:
reacting a substantially monodispersed mixture of compounds having the structure of Formula IV with a compound capable of ionizing the hydroxyl moiety of the compound of Formula IV under conditions sufficient to provide the substantially monodispersed mixture of compounds having the structure of Formula I.
22. The method according to Claim 21, wherein the molar ratio of the compound capable of ionizing the hydroxyl moiety to the compound of Formula I is greater than about 1:1.
23. The method according to Claim 21, wherein the molar ratio of the compound capable of ionizing the hydroxyl moiety to the compound of Formula I is at least about 2:1.
24. The method according to Claim 21, wherein the compound capable of ionizing the hydroxyl moiety is a strong base.
25. The method according to Claim 24, wherein the strong base is selected from the group consisting of sodium hydride, potassium hydride, sodium t-butoxide, potassium t-butoxide, and sodium amide.
26. The method according to Claim 24, wherein the strong base is sodium hydride.
27. The method according to Claim 20, wherein the reacting of a substantially monodispersed mixture of compounds of Formula IV under conditions sufficient to provide a substantially monodispersed mixture of compounds of Formula I is performed at a temperature between about 0°C and about 40°C.
28. The method according to Claim 20, wherein the reacting of a substantially monodispersed mixture of compounds of Formula IV under conditions sufficient to provide a substantially monodispersed mixture of compounds of Formula I is performed at a temperature between about 15°C and about 35°C.
29. The method according to Claim 20, wherein the reacting of a substantially monodispersed mixture of compounds of Formula IV under conditions sufficient to provide a substantially monodispersed mixture of compounds of Formula I is performed for a period of time between about 0.25 and about 4 hours.
30. The method according to Claim 1, wherein at least about 96, 97, 98 or 99 percent of the compounds in the mixture of polymers of Formula III have the same molecular weight.
31. The method according to Claim 1, wherein the mixture of polymers of Formula III is a monodispersed mixture.
32. A monodispersed mixture of polymers comprising polyethylene glycol moieties, said polymers synthesized by the method of Claim 1.
33. A method of synthesizing a substantially monodispersed mixture of polymers comprising polyethylene glycol moieties, said method comprising:
reacting a substantially monodispersed mixture of compounds having the structure of Formula I:
R1(OC2H4)m-O-X1+ (I) wherein R1 is H or lower alkyl; m is from 1 to 25; and X1+ is a positive ion, with a substantially monodispersed mixture of compounds having the structure of Formula II:
R2(OC2H4)n-OMs (II) wherein R2 is H or lower alkyl; and n is from 1 to 25, under conditions sufficient to provide a substantially monodispersed mixture of polymers comprising polyethylene glycol moieties and having the structure of Formula III:
R2(OC2H4)m+n-OR1 (III).
reacting a substantially monodispersed mixture of compounds having the structure of Formula I:
R1(OC2H4)m-O-X1+ (I) wherein R1 is H or lower alkyl; m is from 1 to 25; and X1+ is a positive ion, with a substantially monodispersed mixture of compounds having the structure of Formula II:
R2(OC2H4)n-OMs (II) wherein R2 is H or lower alkyl; and n is from 1 to 25, under conditions sufficient to provide a substantially monodispersed mixture of polymers comprising polyethylene glycol moieties and having the structure of Formula III:
R2(OC2H4)m+n-OR1 (III).
34. The method according to Claim 33, wherein m + n is at least 7.
35. The method according to Claim 33, wherein R1 is H and R2 is methyl.
36. The method according to Claim 33, further comprising:
reacting the substantially monodispersed mixture of polymers comprising polyethylene glycol moieties and having the structure of Formula III:
R2(OC2H4)m+n-OR1 (III) wherein R1 is H and R2 is lower alkyl, with a methane sulfonyl halide under conditions sufficient to provide a substantially monodispersed mixture of polymers having the structure of Formula IX:
R2(OC2H4)m+n-OMs (IX); and reacting the substantially monodispersed mixture of polymers having the structure of Formula IX with a substantially monodispersed mixture of compounds having the structure of Formula X:
H(OC2H4)p-O-X2+ (X) wherein X2+ is a positive ion; and p is from 1 to 25, under conditions sufficient to provide a substantially monodispersed mixture of polymers having the structure of Formula XI:
R2(OC2H4)m+n+p-OH (XI).
reacting the substantially monodispersed mixture of polymers comprising polyethylene glycol moieties and having the structure of Formula III:
R2(OC2H4)m+n-OR1 (III) wherein R1 is H and R2 is lower alkyl, with a methane sulfonyl halide under conditions sufficient to provide a substantially monodispersed mixture of polymers having the structure of Formula IX:
R2(OC2H4)m+n-OMs (IX); and reacting the substantially monodispersed mixture of polymers having the structure of Formula IX with a substantially monodispersed mixture of compounds having the structure of Formula X:
H(OC2H4)p-O-X2+ (X) wherein X2+ is a positive ion; and p is from 1 to 25, under conditions sufficient to provide a substantially monodispersed mixture of polymers having the structure of Formula XI:
R2(OC2H4)m+n+p-OH (XI).
37. A method of synthesizing a substantially monodispersed mixture of polymers comprising polyethylene glycol moieties, said method comprising:
reacting a substantially monodispersed mixture of compounds having the structure of Formula I:
R1(OC2H4)m-O-X1+ (I) wherein R1 is lower alkyl; m is from 1 to 25; and X1+ is a positive ion, with a substantially monodispersed mixture of compounds having the structure of Formula II:
R2(OC2H4)n-OMs (II) wherein n is from 1 to 25; and R2 is an ester of a fatty acid, under conditions sufficient to provide a substantially monodispersed mixture of polymers comprising polyethylene glycol moieties and having the structure of Formula III:
R2(OC2H4)m+n-OR1 (III).
reacting a substantially monodispersed mixture of compounds having the structure of Formula I:
R1(OC2H4)m-O-X1+ (I) wherein R1 is lower alkyl; m is from 1 to 25; and X1+ is a positive ion, with a substantially monodispersed mixture of compounds having the structure of Formula II:
R2(OC2H4)n-OMs (II) wherein n is from 1 to 25; and R2 is an ester of a fatty acid, under conditions sufficient to provide a substantially monodispersed mixture of polymers comprising polyethylene glycol moieties and having the structure of Formula III:
R2(OC2H4)m+n-OR1 (III).
38. The method according to Claim 37, further comprising:
reacting the substantially monodispersed mixture of polymers having the structure of Formula III under conditions sufficient to hydrolyze the ester moiety to provide a carboxylic acid moiety.
reacting the substantially monodispersed mixture of polymers having the structure of Formula III under conditions sufficient to hydrolyze the ester moiety to provide a carboxylic acid moiety.
39. The method according to Claim 37, further comprising:
reacting a substantially monodispersed mixture of compounds having the structure of Formula VI:
R2-OMs (VI) wherein R2 is an ester of a fatty acid, with a substantially monodispersed mixture of compounds having the structure of Formula VII:
R3(OC2H4)n-O-X2+ (VII) wherein R3 is benzyl, trityl, or THP; n is from 1 to 25; and X2+ is a positive ion;
under conditions sufficient to provide a substantially monodispersed mixture of compounds having the structure of Formula VIII:
R3(OC2H4)n-OR2 (VIII);
reacting the substantially monodispersed mixture of compounds having the structure of Formula VIII under conditions sufficient to provide a substantially monodispersed mixture of compounds having the structure of Formula V:
H(OC2H4)n-OR2 (V); and reacting the substantially monodispersed mixture of compounds having the structure of Formula V under conditions sufficient to provide a substantially monodispersed mixture of compounds having the structure of Formula II.
reacting a substantially monodispersed mixture of compounds having the structure of Formula VI:
R2-OMs (VI) wherein R2 is an ester of a fatty acid, with a substantially monodispersed mixture of compounds having the structure of Formula VII:
R3(OC2H4)n-O-X2+ (VII) wherein R3 is benzyl, trityl, or THP; n is from 1 to 25; and X2+ is a positive ion;
under conditions sufficient to provide a substantially monodispersed mixture of compounds having the structure of Formula VIII:
R3(OC2H4)n-OR2 (VIII);
reacting the substantially monodispersed mixture of compounds having the structure of Formula VIII under conditions sufficient to provide a substantially monodispersed mixture of compounds having the structure of Formula V:
H(OC2H4)n-OR2 (V); and reacting the substantially monodispersed mixture of compounds having the structure of Formula V under conditions sufficient to provide a substantially monodispersed mixture of compounds having the structure of Formula II.
40. The method according to Claim 39, wherein R2 is an ester of a fatty acid having the formula:
R4O(O)C(CH2)q~
wherein R4 is lower alkyl, and q is from 1 to 24.
R4O(O)C(CH2)q~
wherein R4 is lower alkyl, and q is from 1 to 24.
41. The method according to Claim 40, wherein R4 is ethyl.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/873,731 | 2001-06-04 | ||
US09/873,731 US6835802B2 (en) | 2001-06-04 | 2001-06-04 | Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties |
PCT/US2002/017619 WO2002098949A1 (en) | 2001-06-04 | 2002-06-04 | Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2449698A1 true CA2449698A1 (en) | 2002-12-12 |
CA2449698C CA2449698C (en) | 2011-06-21 |
Family
ID=25362209
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2449698A Expired - Fee Related CA2449698C (en) | 2001-06-04 | 2002-06-04 | Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties |
Country Status (13)
Country | Link |
---|---|
US (3) | US6835802B2 (en) |
EP (1) | EP1397413B1 (en) |
JP (1) | JP4463454B2 (en) |
AR (1) | AR034085A1 (en) |
AT (1) | ATE302229T1 (en) |
AU (1) | AU2002259338B2 (en) |
BR (1) | BR0106838B1 (en) |
CA (1) | CA2449698C (en) |
DE (1) | DE60205624T2 (en) |
DK (1) | DK1397413T3 (en) |
ES (1) | ES2247328T3 (en) |
TW (1) | TW591053B (en) |
WO (1) | WO2002098949A1 (en) |
Families Citing this family (86)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7642323B2 (en) | 1997-11-06 | 2010-01-05 | Nektar Therapeutics | Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation |
US6828305B2 (en) * | 2001-06-04 | 2004-12-07 | Nobex Corporation | Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
US7713932B2 (en) * | 2001-06-04 | 2010-05-11 | Biocon Limited | Calcitonin drug-oligomer conjugates, and uses thereof |
US6835802B2 (en) * | 2001-06-04 | 2004-12-28 | Nobex Corporation | Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties |
US6713452B2 (en) | 2001-06-04 | 2004-03-30 | Nobex Corporation | Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
US6828297B2 (en) * | 2001-06-04 | 2004-12-07 | Nobex Corporation | Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
DK1430082T3 (en) | 2001-09-07 | 2010-01-18 | Biocon Ltd | Process for the Synthesis of Insulin Polypeptide Oligomer Conjugates and Proinsulin Polypeptide Oligomer Conjugates and Method for Synthesis thereof |
US7196059B2 (en) * | 2001-09-07 | 2007-03-27 | Biocon Limited | Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith |
US7056500B2 (en) * | 2001-10-18 | 2006-06-06 | Nektar Therapeutics Al, Corporation | Polymer conjugates of opioid antagonists |
US20040152769A1 (en) * | 2002-11-09 | 2004-08-05 | Ekwuribe Nnochiri Nkem | Modified carbamate-containing prodrugs and methods of synthesizing same |
CA2504287A1 (en) * | 2002-11-26 | 2004-06-10 | Nobex Corporation | Natriuretic compounds, conjugates, and uses thereof |
CA2515889C (en) | 2003-02-14 | 2015-07-14 | Quanta Biodesign, Ltd. | The selective and specific preparation of discrete peg compounds |
ES2341960T3 (en) | 2003-07-22 | 2010-06-30 | Nektar Therapeutics | PROCEDURES FOR PREPARING FUNCTIONALIZED POLYMERS FROM POLYMERIC ALCOHOLS. |
US20060182692A1 (en) | 2003-12-16 | 2006-08-17 | Fishburn C S | Chemically modified small molecules |
KR101168620B1 (en) | 2003-12-16 | 2012-08-03 | 넥타르 테라퓨틱스 | Pegylated small molecules |
US8329958B2 (en) | 2004-07-02 | 2012-12-11 | Biocon Limited | Combinatorial synthesis of PEG oligomer libraries |
ES2618028T3 (en) | 2004-07-19 | 2017-06-20 | Biocon Limited | Insulin-oligomer conjugates, formulations and uses thereof. |
WO2006076471A2 (en) * | 2005-01-12 | 2006-07-20 | Nobex Corporation | Bnp conjugates and methods of use |
EP1926768B1 (en) | 2005-07-18 | 2011-09-14 | Nektar Therapeutics | Branched functionalized polymers using branched polyol cores |
DE602006014477D1 (en) * | 2005-08-30 | 2010-07-08 | Mazda Motor | Vehicle hood |
US20070072838A1 (en) * | 2005-09-26 | 2007-03-29 | Pharmacyclics, Inc. | High-purity texaphyrin metal complexes |
JP5151152B2 (en) * | 2006-03-29 | 2013-02-27 | 栗田工業株式会社 | Nanofiltration membrane or reverse osmosis membrane rejection rate improver, rejection rate improvement method, nanofiltration membrane or reverse osmosis membrane, water treatment method, and water treatment apparatus |
US9782488B2 (en) | 2007-03-12 | 2017-10-10 | Nektar Therapeutics | Oligomer-beta blocker conjugates |
US8173666B2 (en) | 2007-03-12 | 2012-05-08 | Nektar Therapeutics | Oligomer-opioid agonist conjugates |
US8598364B2 (en) | 2007-03-12 | 2013-12-03 | Nektar Therapeutics | Oligomer-protease inhibitor conjugates |
CN101631569B (en) | 2007-03-12 | 2012-11-14 | 尼克塔治疗公司 | Oligomer-antihistamine conjugates |
KR101568428B1 (en) | 2007-03-12 | 2015-11-11 | 넥타르 테라퓨틱스 | oligomer-opioid agonist conjugates |
US8389759B2 (en) | 2007-03-12 | 2013-03-05 | Nektar Therapeutics | Oligomer-anticholinergic agent conjugates |
US10512644B2 (en) | 2007-03-12 | 2019-12-24 | Inheris Pharmaceuticals, Inc. | Oligomer-opioid agonist conjugates |
US8748648B2 (en) | 2007-09-06 | 2014-06-10 | Nektar Therapeutics | Oligomer-calcium channel blocker conjugates |
US8741858B2 (en) | 2007-09-21 | 2014-06-03 | Zhongxu Ren | Oligomer-nucleoside phosphate conjugates |
US8796248B2 (en) | 2007-10-05 | 2014-08-05 | Nektar Therapeutics | Oligomer-corticosteroid conjugates |
AU2008313248B2 (en) * | 2007-10-16 | 2012-04-26 | Biocon Limited | An orally administerable solid pharmaceutical composition and a process thereof |
US8853247B2 (en) | 2007-11-02 | 2014-10-07 | Nektar Therapeutics | Oligomer-nitroimidazole anti-infective conjugates |
WO2009067175A2 (en) | 2007-11-16 | 2009-05-28 | Nektar Therapeutics Al, Corporation | Oligomer-dantrolene conjugates and related compounds |
MX2010005813A (en) | 2007-11-28 | 2010-06-15 | Nektar Therapeutics | Oligomer-tricyclic conjugates. |
US8685979B2 (en) | 2008-01-25 | 2014-04-01 | Nektar Therapeutics | Oligomer-diarylpiperazine conjugates |
EP2254601B1 (en) | 2008-02-08 | 2019-05-29 | Nektar Therapeutics | Oligomer-cannabinoid conjugates |
US8466276B2 (en) | 2008-02-22 | 2013-06-18 | Nektar Therapeutics | Oligomer conjugates of heteropentacyclic nucleosides |
WO2009114151A1 (en) | 2008-03-12 | 2009-09-17 | Nektar Therapeutics | Oligomer-amino acid and olgomer-atazanavir conjugates |
WO2009114153A1 (en) | 2008-03-12 | 2009-09-17 | Nektar Therapeutics | Oligomer-foscarnet conjugates |
WO2009126333A1 (en) | 2008-04-11 | 2009-10-15 | Nektar Therapeutics | Oligomer-aryloxy-substituted propanamine conjugates |
US9095621B2 (en) | 2008-04-25 | 2015-08-04 | Nektar Therapeutics | Oligome-bis-chromonyl compound conjugates |
WO2009151590A2 (en) | 2008-06-09 | 2009-12-17 | Nektar Therapeutics | Methods of treating cyp2d6 alternative metabolizers |
CN102099397B (en) * | 2008-07-14 | 2012-12-12 | 拜康有限公司 | A method of synthesizing a substantially monodispersed mixture of oligomers |
WO2010033195A1 (en) | 2008-09-16 | 2010-03-25 | Nektar Therapeutics | Pegylated opioids with low potential for abuse |
WO2010033219A2 (en) | 2008-09-17 | 2010-03-25 | Nektar Therapeutics | Protease inhibitors having enhanced features |
US20110166063A1 (en) | 2008-09-19 | 2011-07-07 | Nektar Therapeutics | Polymer conjugates of therapeutic peptides |
AU2010208274B2 (en) | 2009-01-28 | 2015-11-05 | Nektar Therapeutics | Oligomer-phenothiazine conjugates |
WO2010099200A1 (en) | 2009-02-24 | 2010-09-02 | Nektar Therapeutics | Oligomer-amino acid conjugates |
US8816077B2 (en) | 2009-04-17 | 2014-08-26 | Nektar Therapeutics | Oligomer-protein tyrosine kinase inhibitor conjugates |
US8530492B2 (en) | 2009-04-17 | 2013-09-10 | Nektar Therapeutics | Oligomer-protein tyrosine kinase inhibitor conjugates |
EP2430003B1 (en) | 2009-05-13 | 2019-02-27 | Nektar Therapeutics | Oligomer-containing substituted aromatic triazine compounds |
US8785661B2 (en) | 2009-05-13 | 2014-07-22 | Nektar Therapeutics | Oligome-containing pyrrolidine compounds |
US20120108501A1 (en) | 2009-06-12 | 2012-05-03 | Nektar Therapeutics | Protease Inhibitors |
EP2456469A1 (en) | 2009-07-21 | 2012-05-30 | Nektar Therapeutics | Oligomer-opioid agonist conjugates |
JP5792175B2 (en) | 2009-09-29 | 2015-10-07 | ウェルズ ファーゴ バンク ナショナル アソシエイション | Oligomer-calcimimetic conjugates and related compounds |
US8722732B2 (en) | 2009-09-29 | 2014-05-13 | Nektar Therapeutics | Oligomer-calcimimetic conjugates and related compounds |
EP2504019A2 (en) | 2009-11-25 | 2012-10-03 | ArisGen SA | Mucosal delivery composition comprising a peptide complexed with a crown compound and/or a counter ion |
US20130023553A1 (en) | 2010-01-12 | 2013-01-24 | Nektar Therapeutics | Pegylated opioids with low potential for abuse and side effects |
WO2011091050A1 (en) | 2010-01-19 | 2011-07-28 | Nektar Therapeutics | Oligomer-tricyclic conjugates |
US9226970B2 (en) | 2010-02-22 | 2016-01-05 | Nektar Therapeutics | Oligomer modified diaromatic substituted compounds |
US9226971B2 (en) | 2010-10-15 | 2016-01-05 | Nektar Therapeutics | N-optionally substituted aryl-2-oligomer-3-alkoxypropionamides |
JP6002144B2 (en) | 2010-12-10 | 2016-10-05 | ネクター セラピューティクス | Hydroxylated tricyclic compounds |
US9540330B2 (en) | 2010-12-15 | 2017-01-10 | Nektar Therapeutics | Oligomer-containing hydantoin compounds |
WO2012083153A1 (en) | 2010-12-16 | 2012-06-21 | Nektar Therapeutics | Oligomer-containing apremilast moiety compounds |
CN111701028A (en) | 2011-05-18 | 2020-09-25 | 梅德瑞斯糖尿病有限责任公司 | Improved peptide medicine for insulin resistance |
CA2836573C (en) | 2011-05-18 | 2022-06-07 | Eumederis Pharmaceuticals, Inc. | Improved peptide pharmaceuticals |
CA2854512A1 (en) | 2011-11-07 | 2013-05-16 | Nektar Therapeutics | Compositions, dosage forms, and co-administration of an opioid agonist compound and an analgesic compound |
US10525054B2 (en) | 2011-11-07 | 2020-01-07 | Inheris Biopharma, Inc. | Compositions, dosage forms, and co-administration of an opioid agonist compound and an analgesic compound |
EP2895457B1 (en) | 2012-09-17 | 2020-05-20 | Nektar Therapeutics | Oligomer-containing benzamide-based compounds |
EP3434696A1 (en) | 2012-11-20 | 2019-01-30 | Mederis Diabetes, LLC | Improved peptide pharmaceuticals for insulin resistance |
DK2922877T3 (en) | 2012-11-20 | 2019-01-02 | Eumederis Pharmaceuticals Inc | IMPROVED PEPTID MEDICINES |
US9353150B2 (en) | 2012-12-04 | 2016-05-31 | Massachusetts Institute Of Technology | Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment |
EP3013812B1 (en) | 2013-06-28 | 2019-10-16 | Nektar Therapeutics | Kappa opioid agonists and uses thereof |
EP3074379B1 (en) | 2013-11-27 | 2019-06-26 | Nektar Therapeutics (India) Pvt. Ltd. | Opioid agonists and uses thereof |
CN103642023B (en) * | 2013-12-20 | 2015-11-18 | 武汉大学 | The synthetic method of a kind of unimodal molecular weight polyoxyethylene glycol and derivative thereof |
WO2015184177A1 (en) | 2014-05-28 | 2015-12-03 | Mederis Diabetes, Llc | Improved peptide pharmaceuticals for insulin resistance |
US10766864B2 (en) | 2015-05-08 | 2020-09-08 | Nektar Therapeutics | Morphinan derivatives for the treatment of neuropathic pain |
US10918627B2 (en) | 2016-05-11 | 2021-02-16 | Massachusetts Institute Of Technology | Convergent and enantioselective total synthesis of Communesin analogs |
US9695138B1 (en) | 2016-10-17 | 2017-07-04 | Acenda Pharma, Inc. | Phenothiazine derivatives and methods of use thereof |
US11932650B2 (en) | 2017-05-11 | 2024-03-19 | Massachusetts Institute Of Technology | Potent agelastatin derivatives as modulators for cancer invasion and metastasis |
US10640508B2 (en) | 2017-10-13 | 2020-05-05 | Massachusetts Institute Of Technology | Diazene directed modular synthesis of compounds with quaternary carbon centers |
EP3735295A1 (en) | 2018-01-03 | 2020-11-11 | Mederis Diabetes, LLC | Improved peptide pharmaceuticals for treatment of nash and other disorders |
JP7342757B2 (en) | 2019-03-29 | 2023-09-12 | 日油株式会社 | Method for producing hetero-type monodisperse polyethylene glycol derivative |
WO2020247054A1 (en) | 2019-06-05 | 2020-12-10 | Massachusetts Institute Of Technology | Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof |
Family Cites Families (153)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3256153A (en) | 1963-02-08 | 1966-06-14 | Smith Kline French Lab | Method of stabilizing wax-fat coating materials and product thereof |
US4003792A (en) | 1967-07-01 | 1977-01-18 | Miles Laboratories, Inc. | Conjugates of acid polysaccharides and complex organic substances |
US3950517A (en) | 1970-05-08 | 1976-04-13 | National Research Development Corporation | Insulin derivatives |
GB1381274A (en) | 1971-01-28 | 1975-01-22 | Nat Res Dev | Insulin derivatives |
US3919411A (en) | 1972-01-31 | 1975-11-11 | Bayvet Corp | Injectable adjuvant and compositions including such adjuvant |
US4044196A (en) | 1972-03-30 | 1977-08-23 | Bayer Aktiengesellschaft | Crosslinked copolymers of α,β-olefinically unsaturated dicarboxylic anhydrides |
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
FR2408387A2 (en) | 1975-06-30 | 1979-06-08 | Oreal | COMPOSITIONS BASED ON AQUEOUS DISPERSIONS OF LIPID SPHERULES |
US4087390A (en) | 1977-02-02 | 1978-05-02 | Eli Lilly And Company | Somatostatin analogs and intermediates thereto |
US4093574A (en) | 1977-02-02 | 1978-06-06 | Eli Lilly And Company | Somatostatin analogs and intermediates thereto |
GB1492997A (en) | 1976-07-21 | 1977-11-23 | Nat Res Dev | Insulin derivatives |
US4223163A (en) | 1976-12-10 | 1980-09-16 | The Procter & Gamble Company | Process for making ethoxylated fatty alcohols with narrow polyethoxy chain distribution |
JPS53116315A (en) | 1977-03-17 | 1978-10-11 | Ueno Seiyaku Oyo Kenkyujo Kk | Powder or granular containing improved sorbinic acid |
US4100117A (en) | 1977-04-21 | 1978-07-11 | Eli Lilly And Company | Somatostatin analogs and intermediates thereto |
US4253998A (en) | 1979-03-09 | 1981-03-03 | American Home Products Corporation | Peptides related to somatostatin |
JPS54148722A (en) | 1978-05-12 | 1979-11-21 | Takeda Chem Ind Ltd | Nonapeptide and its preparation |
US4277394A (en) | 1979-04-23 | 1981-07-07 | Takeda Chemical Industries, Ltd | Tetrapeptidehydrazide derivatives |
GB2051574B (en) | 1979-05-10 | 1984-01-18 | Kyoto Pharma Ind | Adjuvant for promoting absorption of pharmacologically active substances through the rectum |
US4469681A (en) | 1979-07-31 | 1984-09-04 | The Rockefeller University | Method and system for the controlled release of biologically active substances to a body fluid |
US4348387A (en) | 1979-07-31 | 1982-09-07 | The Rockefeller University | Method and system for the controlled release of biologically active substances to a body fluid |
FR2465486A1 (en) | 1979-09-21 | 1981-03-27 | Roussel Uclaf | NEW APPLICATION USING LH-RH OR AGONISTS |
JPS5692846A (en) | 1979-12-27 | 1981-07-27 | Takeda Chem Ind Ltd | Tetrapeptide derivative and its preparation |
US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
EP0092918B1 (en) | 1982-04-22 | 1988-10-19 | Imperial Chemical Industries Plc | Continuous release formulations |
US4698264A (en) | 1982-08-02 | 1987-10-06 | Durkee Industrial Foods, Corp. | Particulate composition and process for making same |
IL68769A (en) | 1983-05-23 | 1986-02-28 | Hadassah Med Org | Pharmaceutical compositions containing insulin for oral administration |
US4585754A (en) | 1984-01-09 | 1986-04-29 | Valcor Scientific, Ltd. | Stabilization of proteins and peptides by chemical binding with chondroitin |
US4684524A (en) | 1984-03-19 | 1987-08-04 | Alza Corporation | Rate controlled dispenser for administering beneficial agent |
US4717566A (en) | 1984-03-19 | 1988-01-05 | Alza Corporation | Dosage system and method of using same |
US4963367A (en) * | 1984-04-27 | 1990-10-16 | Medaphore, Inc. | Drug delivery compositions and methods |
US4849405A (en) | 1984-05-09 | 1989-07-18 | Synthetic Blood Corporation | Oral insulin and a method of making the same |
US4963526A (en) * | 1984-05-09 | 1990-10-16 | Synthetic Blood Corporation | Oral insulin and a method of making the same |
US4839341A (en) | 1984-05-29 | 1989-06-13 | Eli Lilly And Company | Stabilized insulin formulations |
US4622392A (en) | 1984-06-21 | 1986-11-11 | Health Research Inc. (Roswell Park Division) | Thiophospholipid conjugates of antitumor agents |
US4629621A (en) | 1984-07-23 | 1986-12-16 | Zetachron, Inc. | Erodible matrix for sustained release bioactive composition |
US4797288A (en) | 1984-10-05 | 1989-01-10 | Warner-Lambert Company | Novel drug delivery system |
US4946828A (en) * | 1985-03-12 | 1990-08-07 | Novo Nordisk A/S | Novel insulin peptides |
US5157021A (en) * | 1985-03-15 | 1992-10-20 | Novo Nordisk A/S | Insulin derivatives and pharmaceutical preparations containing these derivatives |
US4917888A (en) | 1985-06-26 | 1990-04-17 | Cetus Corporation | Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation |
SE457326B (en) | 1986-02-14 | 1988-12-19 | Lejus Medical Ab | PROCEDURES FOR PREPARING A QUICK SUBSTANTIAL CANDLES CONTAINING BLA MICROCRISTALLIN CELLULOSA |
US4801575A (en) | 1986-07-30 | 1989-01-31 | The Regents Of The University Of California | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
ZA877505B (en) | 1986-10-14 | 1989-05-30 | Lilly Co Eli | Process for transforming a human insulin precursor to human insulin |
GB8706313D0 (en) * | 1987-03-17 | 1987-04-23 | Health Lab Service Board | Treatment & prevention of viral infections |
US5093198A (en) * | 1987-06-19 | 1992-03-03 | Temple University | Adjuvant-enhanced sustained release composition and method for making |
DE3721721C1 (en) * | 1987-07-01 | 1988-06-09 | Hoechst Ag | Process for coating granules |
US5080891A (en) | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
JPH01207320A (en) * | 1988-02-15 | 1989-08-21 | Daicel Chem Ind Ltd | Production of aromatic polyether |
JPH01308231A (en) * | 1988-06-03 | 1989-12-12 | Takeda Chem Ind Ltd | Stabilized pharmaceutical composition and production thereof |
US5055300A (en) * | 1988-06-17 | 1991-10-08 | Basic Bio Systems, Inc. | Time release protein |
DK336188D0 (en) * | 1988-06-20 | 1988-06-20 | Nordisk Gentofte | propeptides |
US5349052A (en) | 1988-10-20 | 1994-09-20 | Royal Free Hospital School Of Medicine | Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor |
US5162430A (en) | 1988-11-21 | 1992-11-10 | Collagen Corporation | Collagen-polymer conjugates |
US5306500A (en) | 1988-11-21 | 1994-04-26 | Collagen Corporation | Method of augmenting tissue with collagen-polymer conjugates |
HUT56857A (en) * | 1988-12-23 | 1991-10-28 | Novo Nordisk As | Human insulin analogues |
US4994439A (en) * | 1989-01-19 | 1991-02-19 | California Biotechnology Inc. | Transmembrane formulations for drug administration |
US5089261A (en) * | 1989-01-23 | 1992-02-18 | Cetus Corporation | Preparation of a polymer/interleukin-2 conjugate |
IT1229514B (en) | 1989-01-30 | 1991-09-03 | Farmhispania S A A Montme | SYNTHETIC AMPHIPHILIC GLYCOCONUGATES FOR NEUROLOGICAL USE. |
FR2643310B1 (en) | 1989-02-21 | 1991-12-27 | Carrie Marcel | SHELF FOR USE OF PURCHASE LIST SUPPORT ADAPTABLE TO THE HANDLING HANDLE OF TROLLEYS, ESPECIALLY SELF-SERVICE STORES |
US5182258A (en) * | 1989-03-20 | 1993-01-26 | Orbon Corporation | Systemic delivery of polypeptides through the eye |
US5122614A (en) | 1989-04-19 | 1992-06-16 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
US5324844A (en) | 1989-04-19 | 1994-06-28 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
US5108568A (en) * | 1989-07-07 | 1992-04-28 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Controlled method of reducing electrophoretic mobility of macromolecules, particles or cells |
US5286637A (en) * | 1989-08-07 | 1994-02-15 | Debiopharm, S.A. | Biologically active drug polymer derivatives and method for preparing same |
US5013556A (en) * | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
DE3937797A1 (en) | 1989-11-14 | 1991-05-16 | Basf Ag | METHOD FOR PRODUCING POLYETHERGLYCOLES |
US5650388A (en) | 1989-11-22 | 1997-07-22 | Enzon, Inc. | Fractionated polyalkylene oxide-conjugated hemoglobin solutions |
US5312808A (en) * | 1989-11-22 | 1994-05-17 | Enzon, Inc. | Fractionation of polyalkylene oxide-conjugated hemoglobin solutions |
US5545618A (en) | 1990-01-24 | 1996-08-13 | Buckley; Douglas I. | GLP-1 analogs useful for diabetes treatment |
US5126324A (en) | 1990-06-07 | 1992-06-30 | Genentech, Inc. | Method of enhancing growth in patients using combination therapy |
IE912365A1 (en) | 1990-07-23 | 1992-01-29 | Zeneca Ltd | Continuous release pharmaceutical compositions |
IL99699A (en) * | 1990-10-10 | 2002-04-21 | Autoimmune Inc | Pharmaceutical oral, enteral or by-inhalation dosage form for suppressing an autoimmune response associated with type i diabetes |
US5595732A (en) * | 1991-03-25 | 1997-01-21 | Hoffmann-La Roche Inc. | Polyethylene-protein conjugates |
JPH06507172A (en) | 1991-04-19 | 1994-08-11 | アフィニティー バイオテック,インコーポレイテッド | Convertible microemulsion formulation |
US5304473A (en) * | 1991-06-11 | 1994-04-19 | Eli Lilly And Company | A-C-B proinsulin, method of manufacturing and using same, and intermediates in insulin production |
IL102633A0 (en) | 1991-07-26 | 1993-01-14 | Smithkline Beecham Corp | Compositions |
US5206219A (en) * | 1991-11-25 | 1993-04-27 | Applied Analytical Industries, Inc. | Oral compositions of proteinaceous medicaments |
US5693769A (en) | 1991-12-13 | 1997-12-02 | Transcell Technologies, Inc. | Glycosylated steroid derivatives for transport across biological membranes and process for making and using same |
DE59309678D1 (en) | 1992-01-17 | 1999-08-05 | Alfatec Pharma Gmbh | Process for the preparation of active ingredient-containing powders, granules or pellets with a framework of hydrophilic macromolecules and their use |
US5262172A (en) | 1992-06-19 | 1993-11-16 | Digestive Care Inc. | Compositions of gastric acid-resistant microspheres containing buffered bile acids |
US5415872A (en) | 1992-06-22 | 1995-05-16 | Digestive Care Inc. | Compositions of gastric acid-resistant microspheres containing salts of bile acids |
US6093391A (en) | 1992-10-08 | 2000-07-25 | Supratek Pharma, Inc. | Peptide copolymer compositions |
GB9316895D0 (en) | 1993-08-13 | 1993-09-29 | Guy S And St Thomas Hospitals | Hepatoselective insulin analogues |
US5298643A (en) | 1992-12-22 | 1994-03-29 | Enzon, Inc. | Aryl imidate activated polyalkylene oxides |
US5349001A (en) | 1993-01-19 | 1994-09-20 | Enzon, Inc. | Cyclic imide thione activated polyalkylene oxides |
US5321095A (en) | 1993-02-02 | 1994-06-14 | Enzon, Inc. | Azlactone activated polyalkylene oxides |
US5298410A (en) | 1993-02-25 | 1994-03-29 | Sterling Winthrop Inc. | Lyophilized formulation of polyethylene oxide modified proteins with increased shelf-life |
US6191105B1 (en) | 1993-05-10 | 2001-02-20 | Protein Delivery, Inc. | Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin |
US5359030A (en) | 1993-05-10 | 1994-10-25 | Protein Delivery, Inc. | Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same |
US5681811A (en) | 1993-05-10 | 1997-10-28 | Protein Delivery, Inc. | Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same |
US5621039A (en) | 1993-06-08 | 1997-04-15 | Hallahan; Terrence W. | Factor IX- polymeric conjugates |
AU7113594A (en) | 1993-06-21 | 1995-01-17 | Enzon, Inc. | Site specific synthesis of conjugated peptides |
TW402506B (en) | 1993-06-24 | 2000-08-21 | Astra Ab | Therapeutic preparation for inhalation |
US5830853A (en) * | 1994-06-23 | 1998-11-03 | Astra Aktiebolag | Systemic administration of a therapeutic preparation |
US5747445A (en) | 1993-06-24 | 1998-05-05 | Astra Aktiebolag | Therapeutic preparation for inhalation |
US5506203C1 (en) | 1993-06-24 | 2001-02-06 | Astra Ab | Systemic administration of a therapeutic preparation |
US6342225B1 (en) | 1993-08-13 | 2002-01-29 | Deutshces Wollforschungsinstitut | Pharmaceutical active conjugates |
PT792290E (en) * | 1993-09-17 | 2002-01-30 | Novo Nordisk As | INSULINA ACILADA |
US5919455A (en) | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US5605976A (en) | 1995-05-15 | 1997-02-25 | Enzon, Inc. | Method of preparing polyalkylene oxide carboxylic acids |
US5951974A (en) | 1993-11-10 | 1999-09-14 | Enzon, Inc. | Interferon polymer conjugates |
DE69434626D1 (en) | 1993-11-17 | 2006-04-20 | Athena Neurosciences Inc | TRANSPARENT LIQUID FOR THE ADMINISTRATION OF CAPTIVATED MEDICAMENTS |
GB9406094D0 (en) | 1994-03-28 | 1994-05-18 | Univ Nottingham And University | Polymer microspheres and a method of production thereof |
US5889153A (en) | 1994-05-20 | 1999-03-30 | Hisamitsu Pharmaceutical Co., Inc. | Protein or polypeptide, method for producing the same and intermediate compound therefor |
US5504188A (en) | 1994-06-16 | 1996-04-02 | Eli Lilly And Company | Preparation of stable zinc insulin analog crystals |
US5461031A (en) | 1994-06-16 | 1995-10-24 | Eli Lilly And Company | Monomeric insulin analog formulations |
US6165976A (en) | 1994-06-23 | 2000-12-26 | Astra Aktiebolag | Therapeutic preparation for inhalation |
US5730990A (en) | 1994-06-24 | 1998-03-24 | Enzon, Inc. | Non-antigenic amine derived polymers and polymer conjugates |
US5738846A (en) | 1994-11-10 | 1998-04-14 | Enzon, Inc. | Interferon polymer conjugates and process for preparing the same |
US5646242A (en) | 1994-11-17 | 1997-07-08 | Eli Lilly And Company | Selective acylation of epsilon-amino groups |
US5693609A (en) | 1994-11-17 | 1997-12-02 | Eli Lilly And Company | Acylated insulin analogs |
SE9404468D0 (en) | 1994-12-22 | 1994-12-22 | Astra Ab | Powder formulations |
US5843866A (en) * | 1994-12-30 | 1998-12-01 | Hampshire Chemical Corp. | Pesticidal compositions comprising solutions of polyurea and/or polyurethane |
US6251856B1 (en) | 1995-03-17 | 2001-06-26 | Novo Nordisk A/S | Insulin derivatives |
US5606038A (en) | 1995-04-10 | 1997-02-25 | Competitive Technologies, Inc. | Amphiphilic polyene macrolide antibiotic compounds |
ES2093593T1 (en) | 1995-05-05 | 1997-01-01 | Hoffmann La Roche | RECOMBINANT OBESE PROTEINS (OB). |
US5824638A (en) * | 1995-05-22 | 1998-10-20 | Shire Laboratories, Inc. | Oral insulin delivery |
US5700904A (en) | 1995-06-07 | 1997-12-23 | Eli Lilly And Company | Preparation of an acylated protein powder |
US5631347A (en) | 1995-06-07 | 1997-05-20 | Eli Lilly And Company | Reducing gelation of a fatty acid-acylated protein |
GB9516268D0 (en) | 1995-08-08 | 1995-10-11 | Danbiosyst Uk | Compositiion for enhanced uptake of polar drugs from the colon |
ES2338431T3 (en) | 1995-09-21 | 2010-05-07 | Genentech, Inc. | VARIANTS OF HUMAN GROWTH HORMONE. |
EP0856026A1 (en) | 1995-10-19 | 1998-08-05 | Receptagen Corporation | Discrete-length polyethylene glycols |
US5766620A (en) * | 1995-10-23 | 1998-06-16 | Theratech, Inc. | Buccal delivery of glucagon-like insulinotropic peptides |
US5639705A (en) | 1996-01-19 | 1997-06-17 | Arco Chemical Technology, L.P. | Double metal cyanide catalysts and methods for making them |
GB9613858D0 (en) | 1996-07-02 | 1996-09-04 | Cortecs Ltd | Hydrophobic preparations |
US5856369A (en) | 1996-07-30 | 1999-01-05 | Osi Specialties, Inc. | Polyethers and polysiloxane copolymers manufactured with double metal cyanide catalysts |
DE19632440A1 (en) * | 1996-08-12 | 1998-02-19 | Basf Ag | Easily prepared and separated catalyst giving pure alkoxylation product with narrow molecular weight distribution |
US6011008A (en) | 1997-01-08 | 2000-01-04 | Yissum Research Developement Company Of The Hebrew University Of Jerusalem | Conjugates of biologically active substances |
US5830918A (en) * | 1997-01-15 | 1998-11-03 | Terrapin Technologies, Inc. | Nonpeptide insulin receptor agonists |
US6310038B1 (en) | 1997-03-20 | 2001-10-30 | Novo Nordisk A/S | Pulmonary insulin crystals |
US6043214A (en) | 1997-03-20 | 2000-03-28 | Novo Nordisk A/S | Method for producing powder formulation comprising an insulin |
PE79099A1 (en) | 1997-06-13 | 1999-08-24 | Lilly Co Eli | STABLE INSULIN FORMULATIONS |
EA200000453A1 (en) | 1997-10-24 | 2000-10-30 | Эли Лилли Энд Компани | COMPOSITIONS OF INSOLUBLE INSULIN |
ZA989744B (en) | 1997-10-31 | 2000-04-26 | Lilly Co Eli | Method for administering acylated insulin. |
US5985263A (en) | 1997-12-19 | 1999-11-16 | Enzon, Inc. | Substantially pure histidine-linked protein polymer conjugates |
US5981709A (en) | 1997-12-19 | 1999-11-09 | Enzon, Inc. | α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same |
US6211144B1 (en) | 1998-10-16 | 2001-04-03 | Novo Nordisk A/S | Stable concentrated insulin preparations for pulmonary delivery |
ES2180511T3 (en) | 1999-01-26 | 2003-02-16 | Lilly Co Eli | MONODISPERSE FORMULATIONS OF HEXAMERIC INSULIN ANALOGS. |
DE19908041A1 (en) | 1999-02-24 | 2000-08-31 | Hoecker Hartwig | Covalently bridged insulin dimers |
US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US6309633B1 (en) | 1999-06-19 | 2001-10-30 | Nobex Corporation | Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same |
KR100345214B1 (en) | 1999-08-17 | 2002-07-25 | 이강춘 | The nasal transmucosal delivery of peptides conjugated with biocompatible polymers |
US6323311B1 (en) | 1999-09-22 | 2001-11-27 | University Of Utah Research Foundation | Synthesis of insulin derivatives |
US7060675B2 (en) | 2001-02-15 | 2006-06-13 | Nobex Corporation | Methods of treating diabetes mellitus |
US6867183B2 (en) | 2001-02-15 | 2005-03-15 | Nobex Corporation | Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith |
US6828297B2 (en) | 2001-06-04 | 2004-12-07 | Nobex Corporation | Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
US6835802B2 (en) | 2001-06-04 | 2004-12-28 | Nobex Corporation | Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties |
US6858580B2 (en) | 2001-06-04 | 2005-02-22 | Nobex Corporation | Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
US6828305B2 (en) | 2001-06-04 | 2004-12-07 | Nobex Corporation | Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
US6713452B2 (en) | 2001-06-04 | 2004-03-30 | Nobex Corporation | Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
US6913903B2 (en) | 2001-09-07 | 2005-07-05 | Nobex Corporation | Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same |
US6770625B2 (en) | 2001-09-07 | 2004-08-03 | Nobex Corporation | Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith |
DK1430082T3 (en) | 2001-09-07 | 2010-01-18 | Biocon Ltd | Process for the Synthesis of Insulin Polypeptide Oligomer Conjugates and Proinsulin Polypeptide Oligomer Conjugates and Method for Synthesis thereof |
-
2001
- 2001-06-04 US US09/873,731 patent/US6835802B2/en not_active Expired - Lifetime
- 2001-10-11 BR BRPI0106838-5A patent/BR0106838B1/en not_active IP Right Cessation
- 2001-10-12 JP JP2001315392A patent/JP4463454B2/en not_active Expired - Fee Related
-
2002
- 2002-06-03 TW TW091111841A patent/TW591053B/en not_active IP Right Cessation
- 2002-06-04 CA CA2449698A patent/CA2449698C/en not_active Expired - Fee Related
- 2002-06-04 ES ES02729341T patent/ES2247328T3/en not_active Expired - Lifetime
- 2002-06-04 AR ARP020102078A patent/AR034085A1/en not_active Application Discontinuation
- 2002-06-04 AT AT02729341T patent/ATE302229T1/en active
- 2002-06-04 DE DE60205624T patent/DE60205624T2/en not_active Expired - Lifetime
- 2002-06-04 WO PCT/US2002/017619 patent/WO2002098949A1/en not_active Application Discontinuation
- 2002-06-04 EP EP02729341A patent/EP1397413B1/en not_active Expired - Lifetime
- 2002-06-04 AU AU2002259338A patent/AU2002259338B2/en not_active Ceased
- 2002-06-04 DK DK02729341T patent/DK1397413T3/en active
-
2003
- 2003-02-14 US US10/367,047 patent/US6815530B2/en not_active Expired - Lifetime
-
2004
- 2004-10-29 US US10/977,973 patent/US7119162B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
JP2003138004A (en) | 2003-05-14 |
JP4463454B2 (en) | 2010-05-19 |
US6835802B2 (en) | 2004-12-28 |
US20030144468A1 (en) | 2003-07-31 |
ATE302229T1 (en) | 2005-09-15 |
DK1397413T3 (en) | 2005-12-12 |
AR034085A1 (en) | 2004-01-21 |
DE60205624T2 (en) | 2006-06-08 |
TW591053B (en) | 2004-06-11 |
BR0106838A (en) | 2003-02-11 |
EP1397413A1 (en) | 2004-03-17 |
US20030004304A1 (en) | 2003-01-02 |
US20050059799A1 (en) | 2005-03-17 |
WO2002098949A1 (en) | 2002-12-12 |
BR0106838B1 (en) | 2011-02-22 |
DE60205624D1 (en) | 2005-09-22 |
US6815530B2 (en) | 2004-11-09 |
EP1397413B1 (en) | 2005-08-17 |
CA2449698C (en) | 2011-06-21 |
US7119162B2 (en) | 2006-10-10 |
AU2002259338B2 (en) | 2007-12-06 |
ES2247328T3 (en) | 2006-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2449698A1 (en) | Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties | |
JP2003138004A5 (en) | ||
KR870001142A (en) | Preparation of Phenyl Ether | |
KR840001952A (en) | N- (4- (3-aminopropyl) aminobutyl) -2- (ω) -guanidino-fatty acid-amido) -2-substituted-ethanamide salts thereof and process for preparing them | |
KR840004073A (en) | Method for preparing 1,4-dihydropyridine | |
ATE275822T1 (en) | QUARTERNARY AMMONIUM AND WATERPROOFING/PRESSERVATION COMPOSITION | |
KR840007011A (en) | Process for preparing cefem compound | |
AU527851B2 (en) | Purine derivatives | |
RU95121634A (en) | METHOD OF OBTAINING ACRYL-PIPERIDINICARBINOLS | |
KR870002086A (en) | Process for preparing indolinone derivative | |
JPH0321015B2 (en) | ||
Ando et al. | Useful application of thiosilanes for preparation of symmetrical and unsymmetrical dialkyl sulfides | |
IE792508L (en) | Piperidylindoles | |
GEP20033119B (en) | Novel Octahydro-6, 10-Dioxo-6H-Pyridazino {1,2-a}{1 Carboxylic Acid Derivatives, Method for Preparation and Use Thereof | |
EP0274601A3 (en) | Synthesis of bis (n-substituted phthalimide) ethers | |
RU2006120444A (en) | APPLICATION OF ASPARAGINIC ACID DERIVATIVE AS A COLLECTOR IN FOAM FLOTATION PROCESSES | |
US4754037A (en) | Process for preparing N-methyl derivatives of ergoline | |
KR890005136A (en) | Azetidinone N-phosphonomethyl ester | |
KR840006485A (en) | [1.2.4] Method for preparing triazolo [4.3-a] quinoxaline-4-amine derivative | |
RU99103923A (en) | Derivatives of 2,6-dihydroxy-4-aminomethylbenzoate | |
AU4387699A (en) | A process for preparing benzocycloheptapyridin-11-ones | |
KR930012700A (en) | Process for preparing N, N'-dialkyl-3,3'-dithiodipropion amide | |
JP3503993B2 (en) | Method for producing N-mono-t-butyloxycarbonylalkylenediamine | |
CA2443431A1 (en) | Process for the preparation of isoflavones | |
JP2876531B1 (en) | 1,8-bis (substituted ethyl) naphthalene compound and method for producing the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20200831 |